Chemical news from Robert Slinn

Filtered chemistry news from Robert Slinn for Reactive Reports.

  • First report on fate of underwater dispersants in Deepwater Horizon oil spill – Scientists are reporting that key chemical components of the 770,000 gallons of oil dispersants applied below the ocean surface in the Deepwater Horizon spill did mix with oil and gas spewing out of the damaged wellhead and remained in the deep ocean for two months or more without degrading. However, it was not possible to determine if the first deep ocean use of oil dispersants worked as planned in breaking up and dissipating the oil.
  • Getting more anti-cancer medicine into the blood – Scientists are reporting successful application of the technology used in home devices to clean jewelry, dentures, and other items to make anticancer drugs like tamoxifen and paclitaxel dissolve more easily in body fluids, so they can better fight the disease.
  • Small particles show big promise in beating unpleasant odors – Scientists are reporting development of a new approach for dealing with offensive household and other odors — one that doesn't simply mask odors like today's room fresheners, but eliminates them at the source. Their research found that a deodorant made from nanoparticles — hundreds of times smaller than peach fuzz — eliminates odors up to twice as effectively as today's gold standard.
  • Chemists turn gold to purple – on purpose – Professor Richard Watt and his chemistry students suspected that a common protein could potentially react with sunlight and harvest its energy – similar to what chlorophyll does during photosynthesis.
  • DMP1, a protein from the SIBLINGs family, inhibits angiogenesis and could lead to new treatments against cancer and other diseases! – A team from the Metastasis Research Laboratory (GIGA-Cancer/Liège University Hospital) has just published, in the prestigious journal BLOOD, their work demonstrating that the DMP1 protein has previously unsuspected anti-angiogenic activities which could be used for the development of new treatments against cancer, but also against diseases in which angiogenesis (the formation of new blood vessels) plays a major role, such as psoriasis, rheumatoid arthritis or diabetic retinopathy.